In human and animal trials, the administration of FGF21 induces weight loss via the leptin pathway and it seems to have favorable effects on lipid and on glucose metabolism and fatty liver disease via decreased lipogenesis and inflammation [27,64]. Here, LEP is linked to fatty liver disease.